Sign In
Buy MNMD
$20.69
+0 (+0%)
At Close: Jun 18, 2026
MindMed to Report First Quarter 2025 Financial Results on May 8, 2025
07:00am, Thursday, 24'th Apr 2025
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain
MindMed Announces New Employee Inducement Grants
04:01pm, Monday, 21'st Apr 2025
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidat
MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)
07:00am, Tuesday, 15'th Apr 2025
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain
MindMed Announces New Employee Inducement Grants
04:01pm, Monday, 24'th Mar 2025
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to trea
Mind Medicine (MindMed) Inc. (MNMD) Q4 2024 Earnings Call Transcript
12:10pm, Thursday, 06'th Mar 2025
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD ) Q4 2024 Earnings Conference Call March 6, 2025 8:00 AM ET Company Participants Stephanie Fagan - Chief Corporate Affairs Officer Rob Barrow - CEO Dan Karlin
MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates
07:00am, Thursday, 06'th Mar 2025
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain
Why Mind Medicine Stock Is Skyrocketing Today
03:35pm, Friday, 14'th Feb 2025
Mind Medicine (MNMD 15.66%) stock is seeing impressive gains Friday. The company's share price was up 16.9% as of 3:15 p.m.
MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder
07:00am, Thursday, 30'th Jan 2025
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain
Why Mind Medicine Stock Is Soaring Today
02:25pm, Tuesday, 07'th Jan 2025
Mind Medicine (MNMD 8.97%) stock is posting big gains in Tuesday's trading. The biotech company's share price was up 8.7% as of 2 p.m.
MindMed Stock Skyrockets 94% Year to Date: What's Driving It?
11:25am, Tuesday, 24'th Dec 2024
2024 was a transformational year for MNMD as it executed many important milestones.
5 Biotech Breakthrough Stocks to Watch in 2025
10:40am, Monday, 23'rd Dec 2024
After a decent first half, the drug and biotech sector saw a major downturn in the second half due to disappointing third-quarter sales and profits, guidance cuts, pipeline setbacks and the appointmen
MindMed to Be Added to the Nasdaq Biotechnology Index
07:00am, Thursday, 19'th Dec 2024
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain heal
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain heal
MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy
07:00am, Tuesday, 03'rd Dec 2024
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain heal
MindMed Announces New Employee Inducement Grants
07:00am, Monday, 02'nd Dec 2024
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat bra
